<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03939390</url>
  </required_header>
  <id_info>
    <org_study_id>IB-0319-001</org_study_id>
    <nct_id>NCT03939390</nct_id>
  </id_info>
  <brief_title>Follicular Phase Stimulation vs. Luteal Phase Stimulation in Patients Diagnosed With Suboptimal Response</brief_title>
  <acronym>SUBLUTEAL</acronym>
  <official_title>Conventional Stimulation in Follicular Phase vs. Luteal Phase Stimulation in Patients With Suboptimal Response. Randomized Clinical Trial. SUBLUTEAL Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Instituto Bernabeu</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Instituto Bernabeu</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to investigate the difference in the number of oocytes obtained by performing
      ovarian stimulation in follicular phase vs. luteal phase in a population of patients with
      previous suboptimal response.

      This is a controlled randomized clinical study.

      We aim to include 41 patients diagnosed with suboptimal response who will undergo an ovarian
      stimulation in order to vitrify and accumulate oocytes.

      The main variable for evaluating the efficacy in this exploratory study will be the number of
      oocyte cumulus complexes obtained.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 17, 2020</start_date>
  <completion_date type="Anticipated">May 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">April 30, 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>number of oocytes</measure>
    <time_frame>at the end of stimulation</time_frame>
    <description>number of oocytes after ovarian stimulation</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">41</enrollment>
  <condition>Improving Ovarian Stimulation; Suboptimal Responders</condition>
  <arm_group>
    <arm_group_label>follicular phase stimulation</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>luteal phase stimulation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>time of administration of Corifollitropin Alfa</intervention_name>
    <description>The treatment will be identical in both arms. The difference between the arms is the moment of the Administration of Corifollitropin Alfa: follicular phase of the menstrual cycle (control group) vs. luteal phase of the menstrual cycle (study group).</description>
    <arm_group_label>luteal phase stimulation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Meets Bologna criteria to be diagnosed as poor responder

          -  Less than 10 oocytes obtained in a prior controlled protocol of conventional ovarian
             stimulation

          -  Age &lt; 41 years

          -  Body Mass Index (BMI) between 18 and 32 kg/m2

          -  Regular menstrual cycles between 21 and 35 days.

          -  Indication for in vitro fertilization

          -  Indication to start stimulation with 150mcg of corifollitropin alpha

          -  Presence of both ovaries

          -  Ability to participate and comply with study protocol

          -  Signing an informed consent form

        Exclusion Criteria:

          -  Presence of follicles larger than 10 mm in the randomization visit

          -  Endometriosis stage III/IV

          -  Patients with less than 4 oocytes in previous ovarian stimulation and poor ovarian
             reserve parameters (as per Bologna criteria)

          -  Concurrent participation in another study
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>41 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Anna Pitas, PhD</last_name>
    <phone>+34663926079</phone>
    <email>apitas@institutobernabeu.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Instituto Bernabeu</name>
      <address>
        <city>Alicante</city>
        <zip>03016</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anna Pitas, PhD</last_name>
      <phone>0034 663 926 079</phone>
      <email>apitas@institutobernabeu.com</email>
    </contact>
    <investigator>
      <last_name>Joaquin Llacer, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>May 3, 2019</study_first_submitted>
  <study_first_submitted_qc>May 3, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 6, 2019</study_first_posted>
  <last_update_submitted>June 19, 2020</last_update_submitted>
  <last_update_submitted_qc>June 19, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 23, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Instituto Bernabeu</investigator_affiliation>
    <investigator_full_name>Joaquín Llácer</investigator_full_name>
    <investigator_title>Dr</investigator_title>
  </responsible_party>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

